Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | PDE4A | P27815 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882423 | 0.87 | PDE4A (0.63) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2886318 | 0.83 | TDP1 (0.52) | TDP1L3MBTL1HPGD | |
| SCHEMBL29174154 | 0.83 | TNF (0.60) | TNFPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL29883153 | 0.83 | TNF (0.60) | TNFPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2885762 | 0.83 | MTNR1A (0.54) | MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL3828331 | 0.83 | MTNR1A (0.48) | TNFMTNR1AMTNR1BPDE4DPDE4A | |
| SCHEMBL8770891 | 0.82 | MTNR1A (0.50) | TNFMTNR1AMTNR1BPDE4DPDE4A | |
| SCHEMBL29184115 | 0.82 | TNF (0.59) | TNFPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2882501 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL2882505 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | MSD K.K. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2042478-A1 | METHOD FOR PRODUCING -DIARYL ELECTRON-WITHDRAWING GROUP SUBSTITUTED COMPOUND | Japan Science and Technology Agency (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | BMP6, GPR6, ACSL6 | TNF 4564/4885MTNR1A 2869/4885MTNR1B 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.